Enhancing Understanding of Pathophysiology & Exploring the Evolving Landscape of FcRn, Complement & B-cell-Targeting Agents to Strengthen Future Treatment Opportunities
Over the past year, the Myasthenia Gravis landscape has transformed from a once-sparse market into a highly competitive, multi-billion-dollar arena, driven by breakthroughs in FcRn inhibition, complement targeting and B-cell modulation. This surge has sparked growing interest in applying these approaches to adjacent neuromuscular and peripheral nerve disorders, yet critical gaps in disease biology, patient stratification and biomarker validation continue to limit clinical success.
The Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit is the first industry-led forum dedicated to transforming the MG, CIDP, GBS and MMN treatment landscapes, bringing together biopharma leaders to tackle the mechanistic and translational challenges shaping this rapidly evolving space.
This meeting is uniquely positioned to address these challenges. Unlike pathway-specific or clinician-led events, it is indication-focused, mechanism-driven and tailored exclusively to drug developers, enabling deeper discussion on pathophysiology, differentiation and translational strategy.
As competition intensifies and more companies enter the space, success will depend on how well you understand, and exploit, the underlying biology. Join your peers to de-risk development, identify new opportunities and gain a competitive edge in one of the fastest-moving areas of immunology and neurology.
Testimonial from the 4th ALS Drug Development Summit 2025:
“I really enjoyed the balance between academic and industry presentation. The atmosphere was very lively and the size of the meeting just right to be able to interact with everyone while having representatives from a wide variety of fields involved in ALS.”
Director, AviadoBio
Testimonial from the 5th ALS Drug Development Summit 2026:
“This conference is a great opportunity for industry and academic experts to discuss the recent advances and remaining key challenges in the field.”
Scientific Director, Rare Neurology, Neuroscience Therapeutic Area Unit, Takeda
Testimonial from the 9th Complement-Based Drug Development Summit 2025:
“Networking with colleagues and deep complement discussions. Program was also well balanced.”
Director, Complement Science, Apellis Pharmaceuticals
Explore the Full Event Guide
- 18+ Industry Expert Speakers Shared Groundbreaking Research & Strategies
- 2 Deep Dive Workshops Dissecting Patient Heterogeneity, Precision Therapeutics & the Translational Gap
- Unmissable networking opportunities, including roundtable discussions and a poster session
- Understand the Underlying Biology of Neuromuscular Autoimmune Disease & Peripheral Neuropathies Through an Industry Lens
Attending Companies Include
Explore Related Events
Explore the Agenda
Uncover how industry leaders are tackling disease biology, biomarkers and translational risk across MG, CIDP, GBS and MMN through data-driven presentations, interactive roundtables and strategic panel discussions.
Partner With Us
Position your solutions at the centre of a rapidly evolving field by engaging directly with biopharma teams seeking to improve models, biomarkers and clinical development strategies.
Join Biopharma Experts
Connect with discovery, translational and clinical experts advancing autoimmune neuromuscular pipelines, and build high-value relationships through focused, peer-driven networking.